

## BIOGRAPHICAL SKETCH

Provide the following information for the proposed network coordinators and members  
Follow this format for each person.

NAME MASSIMO FEDERICI	POSITION TITLE PROFESSOR OF MEDICINE		
EDUCATION/TRAINING ( <i>Begin with baccalaureate or other initial professional education, and include postdoctoral training.</i> )			
INSTITUTION AND LOCATION	DEGREE (if applicable)	YEAR(s)	FIELD OF STUDY
MEDICAL DOCTOR - University of Rome	MD	6	Medicine
Board of Internal Medicine - University of Rome	MD	1	Medicine
Research Fellow- Harvard Medical School – Joslin Diabetes Center	MD	1	Metabolism
Board of Endocrinology	MD	5	Endocrinology

### A. Positions and Honors (chronological order)

**1999-2002** University of Rome Tor Vergata, Italy: Assistant Professor of Internal Medicine and Clinical Registrar at the Dept. of Medicine at Tor Vergata University Hospital .  
**2002-2008** University of Rome Tor Vergata, Italy: Associate Professor of Internal Medicine, Atherosclerosis and Metabolism  
**2005** Morgagni Silver Prize  
**2006** EASD Rising Star Lecture  
**2006-present** University of Rome Tor Vergata, School of Medicine: Professor of Medicine and Nutrition  
**2008-present** University of Rome Tor Vergata Hospital "Policlinico Tor Vergata", Director of the Center for Atherosclerosis  
**2007-present** Managing Editor, Acta Diabetologica  
**2008-present** Associate Editor, Atherosclerosis  
**2010** Alceone SID Prize  
**2010-2015** Adjunct Professor of Medicine, Division of Diabetes, Department of Medicine, University of Texas Health Science Center at San Antonio

### B. Clinical Activities

The **Center for Atherosclerosis at the University of Tor Vergata** Medical School Hospital (Policlinico Tor Vergata) has expertise in the treatment of cardiovascular risk factors including **Dyslipidemia, Obesity, Hypertension, Diabetes with cardiovascular and/or microvascular complications and Geriatric Medicine**. The Center for Atherosclerosis has a database record of almost 16.000 patients, who have been followed up for metabolic control since 2001 under the recognition of Italian Health System.

**Clinical resources:** 8 Day Hospital beds and 6 Ambulatory Rooms dedicated to Metabolic Disorders. 1 station for Euglycemic Hyperinsulinemic Clamp. 2 ultrasound diagnostic imaging systems (ESAOTE-Technos-MP and GElogiq MS) for screening of vascular, liver and kidney disorders. DEXA for body composition (Hologic Delphi-QDR). Tanita body composition instrument (BC420-MA). 8 24hBPM instruments (InterMed). EndoPAT for endothelial dysfunction.

The Clinical team is composed by Medical Doctors and Nurses all trained to take care of metabolic and vascular disorders; moreover, the team is also expert in Geriatric Medicine including tests to evaluate cognitive function and physical activity. The team is also trained for the preparation of human specimens (preparation of human monocytes for RNA/Protein extraction, collection of serum, plasma, urine and feces, extraction of DNA) for translational studies.

### Clinical Registries

1) The Italian FLORINASH cohort: Partners in this project have collected the FLORINASH cohorts (396 obese subjects, 68% of females, 20 to 70 years and with a Body Mass Index (BMI) range from 30.9 to 67.96 kg/m<sup>2</sup> see [www.florinash.org](http://www.florinash.org) for details) which was established 7 years ago. More than 150 clinical parameters including baseline evaluation included insulin resistance/secretion (fasted glycemia, euglycemic-hyperinsulinemic clamp/IVGTT/OGTT-derived indexes), carotid intima media thickness (CIMT), ultrasound evaluation of liver steatosis, functional markers, serum and OMICs data (metabolomics, urine proteomics, metagenomic) /transcriptomics, fecal metagenomics and 88 liver transcriptomic data are available on those patients.

2) The Tor Vergata Atherosclerosis Registry includes 490 patients (362 men and 128 women), aged between 32 and 94 years old, with a BMI range from 16,4 to 47,01 kg/m<sup>2</sup> and presence of mono- or polivascular atherosclerosis disease enrolled from 1<sup>st</sup> January 2007.to date. We evaluated inflammatory biomarkers, glucose and lipid metabolism and more than 50 clinical parameters. Moreover the Registry includes a biobank of 300 carotid artery plaques. Patients enrolled were followed up for 1 months-9 years to evaluate cardiovascular death, death for any reason and cardiovascular events.

3) The *Italian EURHYTHDIA cohort* includes almost 400 subjects with active or past nightshift activity (80% women), aged between 30 and 60 years old, with a BMI from 20 to 32. The cohort is under recruitment

4) Participation to LIPIGEN Registry

<i>H-index (Scopus)</i>	42
<i>Total Citations (Scopus)</i>	4632